Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program October 16, 2025 8:00 AM EDT
Company Participants
Marcio Souza – President, CEO & Director
Conference Call Participants
Daniel Ferry – Lifesci Advisors, LLC
Ritu Baral – TD Cowen, Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Joon Lee – Truist Securities, Inc., Research Division
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Brian Skorney – Robert W. Baird & Co. Incorporated, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Francois Brisebois
Justin Walsh – JonesTrading Institutional Services, LLC, Research Division
Ami Fadia – Needham & Company, LLC, Research Division
Presentation
Operator
Good day. Thank you for standing by. Welcome to the Praxis Precision Medicines Essential3 Topline Results Conference Call. [Operator Instructions] Please note that today’s conference may be recorded.
I will now hand the conference over to your speaker host, Dan Ferry. Please go ahead.
Daniel Ferry
Lifesci Advisors, LLC
Good morning, and welcome to the Praxis Precision Medicines Essential3 Topline Results Conference Call. This call is being webcast live and can be accessed on the Investors section of Praxis’ website at www.praxismedicines.com.
Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company’s future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent Praxis’ views as of today, they should not be relied upon as representing the company’s views in the future. Praxis may update these statements in the future, but is not taking on an obligation to do so. Please refer to Praxis’ most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company’s business.
Credit: Source link
